Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma

Table 4

Clinical information of LUAD patients in the testing set.

	Low risk ()	High risk ()	value
Age
<65	41 (36.6%)	53 (46.1%)	0.189
>65	71 (63.4%)	62 (53.9%)
Event
Yes	22 (19.6%)	34 (29.6%)	0.114
No	90 (80.4%)	81 (70.4%)
Gender
Female	62 (55.4%)	59 (51.3%)	0.632
Male	50 (44.6%)	56 (48.7%)
T
T1	42 (37.5%)	30 (26.1%)	0.00148
T2	62 (55.4%)	57 (49.6%)
T3	3 (2.7%)	20 (17.4%)
T4	5 (4.5%)	8 (7.0%)
N
N0	94 (83.9%)	71 (61.7%)	<0.001
N1	13 (11.6%)	23 (20.0%)
N2	5 (4.5%)	21 (18.3%)
Tumor stage
Stage I	77 (68.8%)	51 (44.3%)	0.00205
Stage II	20 (17.9%)	32 (27.8%)
Stage III	9 (8.0%)	23 (20.0%)
Stage IV	6 (5.4%)	9 (7.8%)
Smoking
≤40 pack years of smoke	75 (67.0%)	61 (53.0%)	0.045
>40 pack years of smoke	37 (33.0%)	54 (47.0%)